Company intelligence
OKYO Pharma
Pioneering Therapies for Neuropathic Corneal Pain and Inflammation. NASDAQ: OKYO
Biotechnology Research
London, GB
11–50 employees
Founded 2018
3 public signals
About OKYO Pharma
OKYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases.
Verified activity
Signals from OKYO Pharma
3 published signals
Presence & Recognition
OKYO Pharma is attending the Cantor Global Healthcare Conference in New York City from September 9 to 11, 2026, to connect with investors and analysts.
Reported by OKYO Pharma
Presence & Recognition
OKYO Pharma is speaking at the Ophthalmology Futures European Forum 2026 on Thursday in London.
Reported by Robert Dempsey
Presence & Recognition
OKYO Pharma will be attending ESCRS 2026 in London from September 11 to 15, 2026, to engage about the next wave of innovation for neuropathic corneal pain and share where urcosimod is headed.
Reported by OKYO Pharma